Filing Flows › Viridian Therapeutics (VRDN) › Q3 2026
Viridian Therapeutics (VRDN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Viridian Therapeutics (VRDN) reported revenue of $25.8M for the third quarter 2026 (Q3 2026), -64% from a year earlier and up 91-fold from the quarter before. Operating margin was -401.8%, net loss $101M (393.0% of revenue).
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.8M | 91× | -64% |
| Operating profit | −$103M | — | — |
| Net earnings | −$101M | — | — |
| Operating cash flow | −$92.8M | — | — |
What changed
Revenue was $25.8M in Q3 2026, down 64% year over year and up 8968% from the previous quarter. Product revenue, net was the largest line at 96% of revenue. License revenue lost $69.9M year over year (down 100%), 156% of the total change.
Operating costs exceeded revenue by $103.5M, an operating margin of -401.8%. Total costs grew 17% against a revenue fall of 64%. The fastest-growing cost line was SG&A (+137%). The quarter ended with a net loss of $101.2M, narrower than the previous quarter's $127.1M loss.
Operating cash flow was −$92.8M. Non-cash charges added back $343K of depreciation and amortization and $17.2M of share-based compensation. Working capital and other items used $9.1M. Capital expenditures of $370K exceeded it, leaving free cash flow of −$93.1M.
Questions
What was Viridian Therapeutics' revenue in the third quarter 2026?
Viridian Therapeutics (VRDN) reported revenue of $25.8M for the third quarter 2026 (Q3 2026), -64% from a year earlier and up 91-fold from the quarter before.
Was Viridian Therapeutics profitable in the third quarter 2026?
Operating loss was $103M (-401.8% of revenue) and net loss $101M.